Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘oral hepatitis C drugs’

Price Drop Following Side Effect Issue with Hepatitis C Pipeline Drug Creates Buying Opportunity

Bristol-Myers disclosed on August 1, 2012 that it has suspended a phase II trial in hepatitis C in which BMS-986094, its nucleotide polymerase inhibitor, was being studied in combination with daclatasvir, its NS5a inhibitor. BMS-986094 has been broadly viewed as the cornerstone of BMY’s effort to develop an all oral combination treatment for hepatitis C […]